SHP.L - Shire plc

LSE - LSE Delayed Price. Currency in GBp
4,690.00
0.00 (0.00%)
At close: 5:30PM GMT
Stock chart is not supported by your current browser
Previous Close4,690.00
Open4,650.50
Bid0.00 x 51000
Ask0.00 x 53800
Day's Range4,600.00 - 4,748.00
52 Week Range2,940.50 - 4,780.00
Volume4,935,340
Avg. Volume7,750,412
Market Cap42.725B
Beta (3Y Monthly)0.96
PE Ratio (TTM)8.94
EPS (TTM)524.80
Earnings DateFeb 11, 2019 - Feb 15, 2019
Forward Dividend & Yield0.26 (0.56%)
Ex-Dividend Date2018-09-06
1y Target Est61.22
  • Bloomberg10 hours ago

    Takeda Mulls Sale of $3 Billion in Emerging-Market Assets

    The company is working with Bank of America Corp. to gauge potential buyer interest in emerging-market assets it acquired through its 2011 purchase of Swiss rival Nycomed, according to the people, who asked not to be identified because the information is private. The medicines, which include over-the-counter and prescription drugs, could fetch about $3 billion, the people said. “No decisions have been made regarding specific assets for potential disposal at this stage,” a spokeswoman for Takeda said in an emailed statement.

  • Takeda Wraps Its Shire Buyout; CEO Sees More Mergers Coming
    Investor's Business Daily5 days ago

    Takeda Wraps Its Shire Buyout; CEO Sees More Mergers Coming

    Takeda Pharmaceutical wrapped its $62 billion acquisition of Shire last week. CEO Christophe Weber predicts it won't be the last merger in the hot biopharma sector.

  • TheStreet.com6 days ago

    Takeda Pharmaceutical CEO Talks Big Pharma Trends

    Big pharmaceutical companies have begun 2019 with a bang. $62 billion buyout of Shire Plc have signaled the acquisition appetite in the space is strong. To understand the pipeline still ahead and the rationale for such massive mergers and acquisitions, TheStreet joined Takeda Pharmaceutical's CEO Christophe Weber on the New York Stock Exchange, shortly after his company rang the opening bell to celebrate the Japanese giant's U.S. listing.

  • GlobeNewswire10 days ago

    Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange

    January 11, 2019 – Shire plc (“Shire”) and Shire Acquisitions Investments Ireland DAC, an Irish designated activity company and wholly-owned subsidiary of Shire (“SAIIDAC”), announced today that they have notified the New York Stock Exchange (the “NYSE”) of their intention to apply for the voluntary delisting of SAIIDAC’s outstanding 1.900% Senior Notes due 2019, 2.400% Senior Notes due 2021, 2.875% Senior Notes due 2023 and 3.200% Senior Notes due 2026 (collectively, the “Notes”), which are guaranteed by Shire.

  • GlobeNewswire12 days ago

    De-listing and cancellation of trading of Shire Shares

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE.

  • GlobeNewswire13 days ago

    Director/PDMR Shareholding

    Director/PDMR Shareholding January 8, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) Notification of transactions by persons discharging managerial responsibilities.

  • GuruFocus.com13 days ago

    5 Companies Hit 52-Week Highs

    Recently, multiple companies have achieved yearly highs

  • Benzinga13 days ago

    The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...

  • Financial Times13 days ago

    [$$] Takeda completes £46bn acquisition of Shire

    Takeda Pharmaceutical has completed its £46bn acquisition of Shire, catapulting the 237-year-old Japanese group into one of the world’s largest drugmakers with combined revenues of $31bn .   The completion ...

  • How Takeda's $62 Billion Shire Deal Reshapes Pharma World
    Bloomberg13 days ago

    How Takeda's $62 Billion Shire Deal Reshapes Pharma World

    Takeda’s purchase was the world’s biggest announced acquisition of 2018, transforming the 237-year-old Japanese company into a top 10 drugmaker with lucrative therapies for rare diseases and a sizable footprint in the U.S. Already in 2019, the Takeda deal has been trumped in size by Bristol-Myers Squibb Co.’s $74 billion agreement last week to buy Celgene Corp. Takeda and Shire’s combined revenue catapult it into the ranks of the global pharmaceutical majors -- the first Japanese company to reach the top 10.

  • GlobeNewswire13 days ago

    Scheme becomes effective

    On May 8, 2018, Shire plc (“Shire”) and Takeda Pharmaceutical Company Limited (“Takeda”) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the “Acquisition”). On January 3, 2019, Shire announced that the Royal Court of Jersey had sanctioned the Scheme at the Court Sanction Hearing held on January 3, 2019.

  • GlobeNewswire14 days ago

    Scheme becomes effective

    On May 8, 2018, Shire plc (“Shire”) and Takeda Pharmaceutical Company Limited (“Takeda”) announced that they had reached agreement on the terms of a recommended cash and share offer to be made by Takeda for the entire issued and to be issued share capital of Shire (the “Acquisition”). On January 3, 2019, Shire announced that the Royal Court of Jersey had sanctioned the Scheme at the Court Sanction Hearing held on January 3, 2019.

  • GlobeNewswire14 days ago

    Holding(s) in Company

    Holding(s) in Company January 7, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.

  • Bristol-Myers Finds a $74 Billion Biotech Bargain
    Bloomberg18 days ago

    Bristol-Myers Finds a $74 Billion Biotech Bargain

    (Bloomberg Opinion) -- During the past 16 months, Celgene Inc. has gone from biotech darling to pariah after a series of research fumbles. On Thursday, Bristol-Myers Squibb Co. — which has had its own share-price stumbles after cancer setbacks — rode to Celgene’s rescue and possibly its own with a $74 billion dollar cash-and-stock deal. 

  • GlobeNewswire18 days ago

    Court sanction of the Scheme

    Shire plc (“Shire”) is pleased to announce that the Royal Court of Jersey has today sanctioned the scheme of arrangement pursuant to Article 125 of the Companies (Jersey) Law 1991 (as amended) (the “Scheme”) by which the recommended cash and share offer made by Takeda Pharmaceutical Company Limited (“Takeda”) for the entire issued and to be issued share capital of Shire (the “Acquisition”) is being implemented. There has been no change to the expected timetable of principal events for the Acquisition set out on pages 1 to 3 of the scheme document published on November 12, 2018 in relation to the Acquisition (the “Scheme Document”). Applications have been made for the suspension of trading in Shire Shares on the London Stock Exchange's main market for listed securities and the listing of Shire Shares on the premium listing segment of the Official List of the UK Listing Authority and such suspensions are expected to take effect from 7.30 a.m. (London time) on January 7, 2019.

  • GlobeNewswire19 days ago

    Holding(s) in Company

    Holding(s) in Company January 2, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.

  • GlobeNewswire19 days ago

    Total voting rights

    Total Voting Rights January 2, 2019 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”), in accordance with 5.6.1R of the Financial Conduct Authority's (the “FCA”).

  • GlobeNewswire21 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire24 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire24 days ago

    Holding(s) in Company

    Holding(s) in Company December 28, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.

  • GlobeNewswire25 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswire28 days ago

    Holding(s) in Company

    Holding(s) in Company December 24, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.

  • GlobeNewswire28 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • GlobeNewswirelast month

    Director Declaration

    Director Declaration December 21, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces that Ian Clark, Non-Executive Director of the Company, is a Non-Executive.

  • GlobeNewswirelast month

    Holding(s) in Company

    Holding(s) in Company December 21, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG)  1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are.